A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial) - European Journal of Cancer
Finding the Right Option: Hormone Receptor-Positive Advanced Breast Cancer (Transcript)
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer N Engl J Med 2012;366:520-9 José Baselga, M.D., Ph.D., Mario Campone, M.D., - ppt video online download
Breast Cancer Trials of Oral Everolimus 2 (BOLERO-2) trial flow diagram... | Download Scientific Diagram
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. | Semantic Scholar
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2† - Annals of Oncology
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial - The Lancet Oncology
Quality-of-life methodology in hormone receptor–positive advanced breast cancer: Current tools and perspectives for the future - ScienceDirect
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy | npj Breast Cancer
Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER
Overall Program Goals. Overall Program Goals Current Approaches. - ppt download
Everolimus-based combination therapies for HR+, HER2− metastatic breast cancer - Cancer Treatment Reviews
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER
Efficacy analysis data from the BOLERO-2 trial and the SOLAR-1 study... | Download Scientific Diagram
AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer | Nature Communications
AFINITOR® (everolimus) Tablets Efficacy Data – HR+/HER2- advanced Breast Cancer | For HCPs
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on
MONALEESA clinical program: a review of ribociclib use in different clinical settings | Future Oncology
The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer | Future Oncology
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 - Annals of Oncology
AFINITOR® (everolimus) Tablets Efficacy Data – HR+/HER2- advanced Breast Cancer | For HCPs
